MEG3 and central nervous system cancer: It was found that MEG3 expression was significantly reduced or completely lost in 25% of neuroblastomas (Astuti et al., 2005), 81% of hepatocellular cancers (Braconi et al., 2011), and 82% of gliomas (Wang et al., 2012).